Citi reports that Novo Nordisk's Wegovy pill is dominating the US oral weight-loss market, with about 152,000 prescriptions in its 24th week post-launch, despite a slight dip due to the Juneteenth holiday. On a four-week average, prescriptions increased by 2%, and Wegovy is prescribed at roughly twice the rate of Eli Lilly's Zepbound at the same launch stage. Eli Lilly's Foundayo, launched in April, trails with 20,594 prescriptions in its tenth week. These figures highlight Wegovy's strong market position amid growing competition in oral GLP-1 weight-loss drugs.
Starting July 1, Medicare will cover obesity drugs for eligible seniors through its new Bridge demonstration program, requiring a $50 monthly copay. This marks a major expansion in access to treatments from Novo Nordisk and Eli Lilly, previously unaf...
GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are driving high demand among employees, but their high costs are causing many large employers to reduce or reconsider coverage. Although oral pills are as expensive as injectables and less effe...
